<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553382</url>
  </required_header>
  <id_info>
    <org_study_id>15-111</org_study_id>
    <nct_id>NCT02553382</nct_id>
  </id_info>
  <brief_title>Fibre Grain Herb Trial in Type 2 Diabetes</brief_title>
  <acronym>FIGHT</acronym>
  <official_title>Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <brief_summary>
    <textblock>
      Despite the availability of multiple medications for the treatment of Type 2 diabetes,
      patients often continue to have difficulty attaining blood glucose targets and managing
      cardiovascular disease risk factors. Recent trends in non-pharmacological therapy have
      created a growing public interest in dietary supplements.

      Research by this group and others support the benefits of whole grains, viscous dietary fibre
      and ginseng in the management of diabetes. The current study investigates whether the
      co-administration of a viscous dietary fibre blend, Salba (a grain rich in omega-3 fatty
      acids), and 2 varieties of ginseng roots will further improve blood sugar control and
      cardiovascular disease risk outcomes in individuals with Type 2 diabetes already receiving
      conventional treatments.

      Patients with Type 2 diabetes receiving the recommended intervention in accordance with the
      Canadian Diabetes Association guidelines will be enrolled in a 6-month clinical study. Half
      of the participants will be randomly assigned to a 4-component intervention that comprises
      the co-administration of these four dietary/herbal supplements in addition to their usual
      treatment regimen; the other half will continue their usual treatment regimen in addition to
      taking high-oat fiber and wheat bran supplements.

      The investigators hypothesize that an intensified, multi-targeted intervention with the
      addition of these dietary and herb components will further improve long-term blood glucose
      control and cardiovascular disease risk factors beyond conventional therapy. If this
      combination of viscous fiber, Salba and ginseng is shown to be beneficial, these remedies
      could complement current conventional therapy for Type 2 diabetes with the goal to further
      improve health outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24h ambulatory systolic blood pressure</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting insulin</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol:HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Non-HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Apo-B</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 24h diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in office systolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in office diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in central systolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in central diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Augmentation index at heart rate 75 bpm</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hs-CRP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dietary, Herbal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary, Herbal</intervention_name>
    <description>Viscous fibre blend and Salba and American and Korean Red Ginseng capsules</description>
    <arm_group_label>Dietary, Herbal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Positive Control</intervention_name>
    <description>Oat bran blend and wheat bran capsules</description>
    <arm_group_label>Positive Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes medically diagnosed for at least 6-months prior to randomization

          -  HbA1c (glycated hemoglobin) between 6.3% and 8.5% at screening

          -  BMI &lt; 35 kg/m2

        Exclusion Criteria:

          -  Insulin therapy

          -  Blood pressure â‰¥ 160/100 mmHg

          -  Serum triglyceride &gt;4.5mmol/L

          -  History of major cardiovascular events (stroke or myocardial infarction)

          -  Gastrointestinal, liver or kidney disease

          -  Consumption of alcohol &gt;2 drinks/day

          -  Current tobacco smokers

          -  Taking the following medications: herbs or supplements that may affect primary or
             secondary outcomes, monoamine oxidase inhibitors (MAOIs) antidepressants and/or
             anticoagulant therapy

          -  Women with hormone sensitive tumors/conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Michael's Hopsital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Vuk Vrhovac, Merkur Hospital</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

